<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html>
    <head>
        <title>Lilly</title>
        <meta http-equiv="content-type" content="text/html; charset=UTF-8">
        <link rel="stylesheet" type="text/css" href="fonts/stylesheet.css">
        <link rel="stylesheet" type="text/css" href="jquery.qtip.css">
        <link rel="stylesheet" type="text/css" href="site.css">
        <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.6.1/jquery.min.js" type="text/javascript"></script>
        <script src="jquery.qtip-1.0.0-rc3-dm.js" type="text/javascript"></script>
        <script src="jquery.bpopup-0.5.1.min.js" type="text/javascript"></script>
        <script src="site.js" type="text/javascript"></script>
        <script type="text/javascript">
            $(document).ready(function() {
                // Match all <A/> links with a title tag and use it as the content (default).
                $('a.tooltip[title]').qtip({
                    position: {
                        adjust: {
                            x: 5,
                            y: 10
                        },
                        corner: {
                            target: 'topRight',
                            tooltip: 'topLeft'
                        }
                    },
                    style: {
                        width: 150,
                        name: 'dark',
                        tip: {
                            corner: 'topLeft',
                            color: '#979797',
                            size: {
                                x: 9,
                                y: 10
                            }
                        }
                    }
                });
                $('a.bigtooltip[title]').qtip({
                    position: {
                        adjust: {
                            x: 5,
                            y: 10
                        },
                        corner: {
                            target: 'topRight',
                            tooltip: 'topLeft'
                        }
                    },
                    style: {
                        width: 236,
                        name: 'dark',
                        tip: {
                            corner: 'topLeft',
                            color: '#979797',
                            size: {
                                x: 9,
                                y: 10
                            }
                        }
                    }
                });
                $('a.bigtooltip_left[title]').qtip({
                    position: {
                        adjust: {
                            x: 0,
                            y: 10
                        },
                        corner: {
                            target: 'topLeft',
                            tooltip: 'topRight'
                        }
                    },
                    style: {
                        width: 580,
                        name: 'dark',
                        tip: {
                            corner: 'topRight',
                            color: '#979797',
                            size: {
                                x: 9,
                                y: 10
                            }
                        }
                    }
                });

                /*
									$('a.tooltip_under[title]').qtip({
										position: {
											corner: {
												target: 'bottomCenter',
												tooltip: 'bottomCenter'
											}
										},
										style: {
											width: 96,
											name: 'gray'
										}
									});

									$('a.bigtooltip_under[title]').qtip({
										position: {
											corner: {
												target: 'bottomCenter',
												tooltip: 'bottomCenter'
											}
										},
										style: {
											width: 191,
											name: 'gray'
										}
									});
									$('.molecule-container li a label').each(function(){
										if($(this).html().length < 20){
											$(this).parent().css('padding-top', '3px');
											$(this).parent().css('line-height', '32px');
											$(this).parent().css('height', '32px');
										}
									});
									*/
                $('a.bigtooltip_under').hover(function() {
                    $(this).addClass('hovered');
                }, function() {
                    $(this).removeClass('hovered');
                });
                $('a.tooltip_under').hover(function() {
                    $(this).addClass('hovered');
                }, function() {
                    $(this).removeClass('hovered');
                });
            });
        </script>
    </head>
    <body>
        <div id="browser_notice">
            This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)
        </div>
        <div id="container">
            <div id="header">
                <img src="./img/header.png" alt="Lilly - Development Pipeline"/>
            </div>
            <div id="content">
                <div id="content-left">

                    <h1 class="DINBold">
                        <a href="index.html">Pipeline Overview</a>
                    </h1>

                    <div class="menu">
                        <h2 class="DINBold">View by Therapeutic Area</h2>
                        <ul>
                            <li>
                                <a href="7.html" class="" title="Cardiovascular">Cardiovascular</a>
                            </li>
                            <li>
                                <a href="8.html" class="" title="Diabetes">Diabetes</a>
                            </li>
                            <li>
                                <a href="13.html" class="active" title="Emerging Markets">Emerging Markets</a>
                            </li>
                            <li>
                                <a href="14.html" class="" title="Immunology">Immunology</a>
                            </li>
                            <li>
                                <a href="9.html" class="" title="Musculoskeletal">Musculoskeletal</a>
                            </li>
                            <li>
                                <a href="10.html" class="" title="Neuroscience">Neuroscience</a>
                            </li>
                            <li>
                                <a href="11.html" class="" title="Oncology">Oncology</a>
                            </li>
                        </ul>

                        <h2 class="DINBold">View by Molecule Type</h2>
                        <ul>
                            <li>
                                <a href="17.html" class="" title="Chemical entity (small)">Chemical entity (small)</a>
                            </li>
                            <li>
                                <a href="18.html" class="" title="Biologic entity (large)">Biologic entity (large)</a>
                            </li>
                        </ul>
                    </div>

                    <p>
                        <a>Pipeline movement since April 19, 2016</a>
                    </p>
                    <p>
                        <a>Pipeline data through<br/>July 19, 2016</a>
                    </p>

                </div>
                <div id="content-center">
                    <h1 class="big_h1">CLINICAL DEVELOPMENT
                        <span>PIPELINE</span>
                    </h1>
                    <div class="cells-container">
                        <div class="cells-container-inner">
                            <h1 class="toggle active">
                                <label class="exp_open"></label>
                                <span>Regulatory Review</span>
                            </h1>
                            <ul class="molecule-container">
                                <li id='cell-1' class=' '>
                                    <table cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td>
                                                <a id="click-content-1" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
                                                    <div class="molecule-inner-content">
                                                        <label>Baricitinib
                                                            <br>rheumatoid
                                                            <br>arthritis</label>
                                                        <label class="toolt">New Molecular Entity</label>
                                                        <label class="click_for_more">Click for more</label>
                                                    </div>
                                                </a>
                                            </td>
                                        </tr>
                                    </table>

                                    <div class="content-popup " id="content-1">
                                        <div class="molecule-title">

                                            <div class="mtitle DINBold">Baricitinib (bar" i sye' ti nib)</div>
                                            <div class="molecule-position">
                                                <label>Regulatory Review</label>
                                                <label>Business area: Bio-Medicines</label>
                                            </div>
                                        </div>

                                        <div class="molecule-description">
                                            LY3009104 (baricitinib, formerly known as JAK1/JAK2 inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of rheumatoid arthritis.<br/><br/>
                                            For more information on baricitinib clinical studies, click
                                            <a href="http://clinicaltrials.gov/ct2/results?term=LY3009104" target="_blank">here</a><br/>
                                            <br>
                                            <p style="font-size:10px;">
                                                NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
                                            <br/><br/>
                                            <h1>
                                                <strong>PRESS RELEASES</strong>
                                                (1/1/2010-7/19/2016)</h1>
                                            <p>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137551">
                                                        <span style="color: #000000;">Results Of Clinical And Patient-Reported Outcomes Data For Baricitinib In Patients With Rheumatoid Arthritis To Be Presented At Annual European Congress Of Rheumatology (EULAR 2016)</span>
                                                    </a>—June 7, 2016<br/><br/></span>
                                            </p>
                                            <p>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137554">
                                                        <span style="color: #000000;">Patient-Reported Outcomes Across Phase 3 Studies Of Baricitinib Demonstrate Statistically Significant Improvements In Physical Function And Quality Of Life Symptoms In Patients With Rheumatoid Arthritis (RA)</span>
                                                    </a>—June 9, 2016<br/><br/></span>
                                            </p>
                                            <p>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137553">
                                                        <span style="color: #000000;">Baricitinib Significantly Reduces Joint Damage Progression In Rheumatoid Arthritis In Patients Who Do Not Respond To Conventional DMARDs</span>
                                                    </a>—June 9, 2016<br/><br/></span>
                                            </p>
                                            <p>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137528">
                                                        <span style="color: #000000;">Phase 3 Study Findings Demonstrate Treatment With Baricitinib Results In Significant Improvements For Patients With Rheumatoid Arthritis Who Had Inadequate Response To Biologics</span>
                                                    </a>—March 31, 2016<br/></span><br/><br/>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137509">
                                                        <span style="color: #000000;">Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis</span>
                                                    </a>—January 19, 2016<br/></span><br/><br/>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137493">
                                                        <span style="color: #000000;">Lilly And Incyte Announce Patients Treated With Baricitinib Demonstrated Significant Improvement In Signs And Symptoms Of Rheumatoid Arthritis Compared With Methotrexate</span>
                                                    </a>—November 7, 2015<br/></span><br/><br/>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137496">
                                                        <span style="color: #000000;">Detailed Results Demonstrate Baricitinib Superiority To Adalimumab In Improving Signs And Symptoms Of Rheumatoid Arthritis</span>
                                                    </a>—November 7, 2015<br/></span><br/><br/>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137489">
                                                        <span style="color: #000000;">Results Of Two Pivotal Baricitinib Trials To Be Presented At 2015 American College Of Rheumatology Annual Meeting</span>
                                                    </a>—November 4, 2015<br/></span><br/><br/>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137486">
                                                        <span style="color: #000000;">Lilly And Incyte Announce Webcast To Discuss Baricitinib Phase 3 Data</span>
                                                    </a>—October 27, 2015<br/></span><br/><br/>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137479">
                                                        <span style="color: #000000;">Baricitinib Demonstrates Superiority To Adalimumab In Improving Signs And Symptoms Of Rheumatoid Arthritis In Pivotal Phase 3 Study</span>
                                                    </a>—October 14, 2015<br/></span><br/><br/>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137468">
                                                        <span style="color: #000000;">Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis</span>
                                                    </a>
                                                    – September 29, 2015</span><br/><br/><br/>
                                                <span style="color: #000000;">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137438">
                                                        <span style="color: #000000;">Lilly And Incyte Unveil Detailed Data On Two Pivotal Studies Of Baricitinib In Rheumatoid Arthritis</span>
                                                    </a>—June 10, 2015<br/><br/></span>
                                            </p>
                                            <span style="color: #000000;">
                                                <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137427">
                                                    <span style="color: #000000;">Lilly And Incyte Announce Webcast To Discuss Baricitinib Phase III Data</span>
                                                </a>—May 28, 2015<br/><br/></span>
                                            <p>
                                                <span style="color: #000000;" data-mce-mark="1">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137393">
                                                        <span style="color: #000000;" data-mce-mark="1">Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3 Study</span>
                                                    </a>
                                                    – February 23, 2015<br/></span><br/><br/>
                                                <span style="color: #000000;" data-mce-mark="1">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137374">
                                                        <span style="color: #000000;" data-mce-mark="1">Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis</span>
                                                    </a>– December 9, 2014
                                                    <br/></span><br/><br/>
                                                <span style="color: #000000;" data-mce-mark="1">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137205">
                                                        <span style="color: #000000;" data-mce-mark="1">Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis</span>
                                                    </a>
                                                    – June 13, 2013<br/></span><br/><br/>
                                                <span style="color: #000000;" data-mce-mark="1">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=135502" target="_blank">
                                                        <span style="color: #000000;" data-mce-mark="1">Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis</span>
                                                    </a>
                                                    – November 13, 2012</span><br/><br/><br/>
                                                <span style="color: #000000;" data-mce-mark="1">
                                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=129335" target="_blank">
                                                        <span style="color: #000000;" data-mce-mark="1">Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis</span>
                                                    </a>
                                                    – June 8, 2012</span>
                                            </p>
                                            <p>
                                                <span style="color: #000000;"></span>
                                            </p>
                                        </div>
                                        <a class="bClose">&nbsp;</a>
                                    </div>
                                    <script type="text/javascript">
                                        $("#click-content-1").bind('click', function() {
                                            $("#content-1").bPopup();
                                            return false;
                                        });
                                    </script>
                                </li>
                                <li id='cell-2' class=' '>
                                    <table cellspacing="0" cellpadding="0">
                                        <tr>
                                            <td>
                                                <a id="click-content-2" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
                                                    <div class="molecule-inner-content">
                                                        <label>Olaratumab<br>
                                                            sarcoma</label>
                                                        <label class="toolt">New Molecular Entity</label>
                                                        <label class="click_for_more">Click for more</label>
                                                    </div>
                                                </a>
                                            </td>
                                        </tr>
                                    </table>

                                    <div class="content-popup " id="content-2">
                                        <div class="molecule-title">

                                            <div class="mtitle DINBold">Olaratumab (oh lar" a tue' mab)
                                            </div>
                                            <div class="molecule-position">
                                                <label>Regulatory Review</label>
                                                <label>Business area: Oncology</label>
                                            </div>
                                        </div>

                                        <div class="molecule-description">
                                            LY3012207 (olaratumab), a biologic entity, is a human IgG1 monoclonal antibody that binds to the platelet derived growth factor receptor alpha (PDGFRα) and blocks PDGFRα activation. LY3012207 is being studied for the treatment of advanced sarcoma.<br/><br>
                                            For more information on olaratumab clinical studies, click
                                            <a href="https://clinicaltrials.gov/ct2/results?term=LY3012207" target="_blank">here</A>.</u>
                                    </a><br/>
                                    <br>
                                    <p style="font-size:10px;">
                                        NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
                                    <br/><br/>
                                    <h1>
                                        <strong>PRESS RELEASES</strong>
                                        (1/1/2010-7/19/2016)</h1>
                                    <div>
                                        <p>
                                            <span style="color: #000000;">
                                                <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137556">
                                                    <span style="color: #000000;">Data In The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase In Overall Survival In Patients With Advanced Soft Tissue Sarcoma, As Reported By Lilly And Memorial Sloan Kettering Researchers</span>
                                                </a>—June 9, 2016<br/><br/></span>
                                        </p>
                                        <p>
                                            <span style="color: #000000;">
                                                <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137539">
                                                    <span style="color: #000000;">FDA Grants Priority Review For Lilly's Olaratumab, An Investigational Medicine For Advanced Soft Tissue Sarcoma</span>
                                                </a>—May 4, 2016</span>
                                        </p>
                                    </div>
                                </div>
                                <a class="bClose">&nbsp;</a>
                            </div>
                            <script type="text/javascript">
                                $("#click-content-2").bind('click', function() {
                                    $("#content-2").bPopup();
                                    return false;
                                });
                            </script>
                        </li>
                        <li id='cell-3' class=' '>
                            <table cellspacing="0" cellpadding="0">
                                <tr>
                                    <td>
                                        <a id="click-content-3" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
                                            <div class="molecule-inner-content">
                                                <label>*Empagliflozin
                                                    <br>
                                                    CV outcomes
                                                    <br>data</label>
                                                <label class="toolt">NILEX</label>
                                                <label class="click_for_more">Click for more</label>
                                            </div>
                                        </a>
                                    </td>
                                </tr>
                            </table>

                            <div class="content-popup " id="content-3">
                                <div class="molecule-title">

                                    <div class="mtitle DINBold">*Empagliflozin CV outcomes data</div>
                                    <div class="molecule-position">
                                        <label>Regulatory Review</label>
                                        <label>Business area: Diabetes</label>
                                    </div>
                                </div>

                                <div class="molecule-description">
                                    Empagliflozin is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). Recently published data from the Empagliflozin Cardiovascular Outcomes Trial, EMPA-REG-OUTCOME, is under regulatory review for inclusion in the currently
                                    approved labels for Empagliflozin. Empagliflozin is being studied in collaboration with Boehringer Ingelheim.
                                    <br/><br>
                                    For more information on Empagliflozin clinical studies, click
                                    <a href="https://clinicaltrials.gov/ct2/results?term=Empagliflozin&Search=Search" target="_blank">here</A>.</u>
                            </a><br/>
                            <br>
                            <p style="font-size:10px;">
                                NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>

                            <br/><br/>
                            <h1>
                                <strong>PRESS RELEASES</strong>
                                (1/1/2010-7/19/2016)</h1>
                            <p>
                                <span style="color: #000000;">
                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137567">
                                        <span style="color: #000000;">FDA Advisory Committee recommends approval of Jardiance® (empagliflozin) for cardiovascular indication in 12-11 vote</span>
                                    </a>—June 28, 2016<br/><br/></span>
                            </p>
                            <p>
                                <span style="color: #000000;">
                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137559">
                                        <span style="color: #000000;">New Jardiance® (Empagliflozin) Data Show That Reduced Risk For Cardiovascular (CV) Death Was Consistent Across Age Groups In Adults With Type 2 Diabetes</span>
                                    </a>—June 12, 2016<br/><br/></span>
                            </p>
                            <p>
                                <span style="color: #000000;">
                                    <span data-mce-mark="1">
                                        <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137533">
                                            <span style="color: #000000;" data-mce-mark="1">Jardiance® (Empagliflozin) To Be Studied For The Treatment Of People With Chronic Heart Failure</span>
                                        </a>
                                    </span>—April 19, 2016<br/><br/></span>
                            </p>
                            <p>
                                <span style="color: #000000;">
                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137511">
                                        <span style="color: #000000;">U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)</span>
                                    </a>—January 25, 2016<br/></span><br/><br/>
                                <span style="color: #000000;">
                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137495">
                                        <span style="color: #000000;">New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline</span>
                                    </a>—November 9, 2015<br/></span><br/><br/>
                                <span style="color: #000000;">
                                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137481">
                                        <span style="color: #000000;">Jardiance® (Empagliflozin) Is The Only Diabetes Medication To Show A Significant Reduction In Both Cardiovascular Risk And Cardiovascular Death In A Dedicated Outcome Trial</span>
                                    </a>—September 17, 2015</span>
                            </p>
                            <div>
                                <span style="color: #000000;"></span>
                            </div>
                        </div>
                        <a class="bClose">&nbsp;</a>
                    </div>
                    <script type="text/javascript">
                        $("#click-content-3").bind('click', function() {
                            $("#content-3").bPopup();
                            return false;
                        });
                    </script>
                </li>
                <li id='cell-4' class=' '>
                    <table cellspacing="0" cellpadding="0">
                        <tr>
                            <td>
                                <a id="click-content-4" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
                                    <div class="molecule-inner-content">
                                        <label>*Empagliflozin + Metformin XR
                                            <br>
                                            diabetes</label>
                                        <label class="toolt">NILEX</label>
                                        <label class="click_for_more">Click for more</label>
                                    </div>
                                </a>
                            </td>
                        </tr>
                    </table>

                    <div class="content-popup " id="content-4">
                        <div class="molecule-title">

                            <div class="mtitle DINBold">Empagliflozin + Metformin XR
                            </div>
                            <div class="molecule-position">
                                <label>Regulatory Review</label>
                                <label>Business area: Diabetes</label>
                            </div>
                        </div>

                        <div class="molecule-description">
                            BI10773 (Empagliflozin) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied as a fixed dose combination with metformin-extended release in collaboration with Boehringer Ingelheim as a treatment
                            for type 2 diabetes.
                            <br/><br>
                            For more information on Empagliflozin + Metformin XR clinical studies, click
                            <a href="https://clinicaltrials.gov/ct2/results?term=Empagliflozin+%2B+Metformin+XR+&Search=Search" target="_blank">here</A>.</u>
                    </a><br/>
                    <br>
                    <p style="font-size:10px;">NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
                    <br/><br/>
                    <h1>
                        <strong>PRESS RELEASES</strong>
                        (1/1/2010-7/19/2016)</h1>
                    <p>None during this time period.</p>
                </div>
                <a class="bClose">&nbsp;</a>
            </div>
            <script type="text/javascript">
                $("#click-content-4").bind('click', function() {
                    $("#content-4").bPopup();
                    return false;
                });
            </script>
        </li>
        <li id='cell-5' class=' '>
            <table cellspacing="0" cellpadding="0">
                <tr>
                    <td>
                        <a id="click-content-5" class=" nilex_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/checked.png" alt=""/>
                            <div class="molecule-inner-content">
                                <label>*Linagliptin + Metformin XR<br>diabetes</label>
                                <label class="toolt">NILEX</label>
                                <label class="click_for_more">Click for more</label>
                            </div>
                        </a>
                    </td>
                </tr>
            </table>

            <div class="content-popup " id="content-5">
                <div class="molecule-title">

                    <div class="minfobg"><img src="./img/checked.png" alt=""/></div>

                    <div class="mtitle DINBold">Linagliptin + Metformin XR</div>
                    <div class="molecule-position">
                        <label>Regulatory Review</label>
                        <label>Business area: Diabetes</label>
                        <label style='display:block;'>Regulatory Approval Achieved</label>
                    </div>
                </div>

                <div class="molecule-description">
                    Linagliptin is a chemical entity that inhibits the enzyme dipeptidyl peptidase 4 (DPP-4). Linagliptin is being studied as a fixed dose combination with metformin-extended release in collaboration with Boehringer Ingelheim as a treatment for type 2
                    diabetes.
                    <br/><br>
                    For more information on Linagliptin + Metformin XR clinical studies, click
                    <a href="https://clinicaltrials.gov/ct2/results?term=Linagliptin+Metformin&Search=Search" target="_blank">here</A>.</u>
            </a><br/>
            <br>
            <p style="font-size:10px;">
                NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
            <br/><br/>
            <h1>
                <strong>PRESS RELEASES</strong>
                (1/1/2010-7/19/2016)</h1>
            <p>
                <span style="color: #000000;">
                    <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137546">
                        <span style="color: #000000;">U.S. FDA Approves Once-Daily Jentadueto® XR (Linagliptin And Metformin Hydrochloride Extended-Release) Tablets For Adults With Type 2 Diabetes</span>
                    </a>—May 31, 2016</span>
            </p>
        </div>
        <a class="bClose">&nbsp;</a>
    </div>
    <script type="text/javascript">
        $("#click-content-5").bind('click', function() {
            $("#content-5").bPopup();
            return false;
        });
    </script>
</li>
<li id='cell-6' class=' '>
    <table cellspacing="0" cellpadding="0">
        <tr>
            <td>
                <a id="click-content-6" class=" nilex_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/checked.png" alt=""/>
                    <div class="molecule-inner-content">
                        <label>Ixekizumab<br>psoriatic arthritis</label>
                        <label class="toolt">NILEX</label>
                        <label class="click_for_more">Click for more</label>
                    </div>
                </a>
            </td>
        </tr>
    </table>

    <div class="content-popup " id="content-6">
        <div class="molecule-title">

            <div class="minfobg"><img src="./img/checked.png" alt=""/></div>

            <div class="mtitle DINBold">Ixekizumab (ix" e kiz' ue mab)</div>
            <div class="molecule-position">
                <label>Regulatory Review</label>
                <label>Business area: Bio-Medicines</label>
                <label style='display:block;'>Regulatory Approval Achieved</label>
            </div>
        </div>

        <div class="molecule-description">
            LY2439821 (ixekizumab) is a biologic entity that neutralizes a soluble factor called interleukin-17A (IL-17). LY2439821 is being studied for the treatment of psoriatic arthritis.
            <br/><br>
            For more information on ixekizumab clinical studies, click
            <a href="http://clinicaltrials.gov/ct2/results?term=LY2439821" target="_blank">here</A>.</u>
    </a><br/>
    <br>
    <p style="font-size:10px;">
        NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
    <br/><br/>
    <h1>
        <strong>PRESS RELEASES</strong>
        (1/1/2010-4/19/2016)</h1>
    <p>
        <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137521">Lilly To Present Phase 3 Data At The American Academy Of Dermatology (AAD) Annual Meeting For Ixekizumab In Psoriasis And Psoriatic Arthritis</a>
        – March 1, 2016<br/><br/>
        <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137494">Patients Show Significant Improvement In Signs And Symptoms Of Psoriatic Arthritis, Less Progression Of Structural Joint Damage When Treated With Ixekizumab For 24 Weeks</a>
        – November 8, 2015<br/><br/>
        <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137406">Lilly's Ixekizumab Met Primary Endpoint In A Phase 3 Study Investigating The Treatment Of Psoriatic Arthritis</a>
        – April 20, 2015<br/><br/>
        <a href="http://lilly.mediaroom.com/index.php?s=9042&item=137469">Lilly To Showcase Data For Investigational Psoriasis Treatment At 24th European Academy Of Dermatology And Venereology Congress</a>
        - October 6, 2015</p>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-6").bind('click', function() {
    $("#content-6").bPopup();
    return false;
});
</script>
</li>
</ul>
</div>
</div>

<div class="cells-container">
<div class="cells-container-inner">
<h1 class="toggle active">
<label class="exp_open"></label>
<span>Phase III</span>
</h1>
<ul class="molecule-container">
<li id='cell-37' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
    <td>
        <a id="click-content-37" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
            <div class="molecule-inner-content">
                <label>Nasal<br>Glucagon<br>hypoglycemia</label>
                <label class="toolt">New Molecular Entity</label>
                <label class="click_for_more">Click for more</label>
            </div>
        </a>
    </td>
</tr>
</table>

<div class="content-popup " id="content-37">
<div class="molecule-title">

    <div class="mtitle DINBold">Nasal Glucagon hypoglycemia</div>
    <div class="molecule-position">
        <label>Phase III</label>
        <label>Business area: Diabetes</label>
    </div>
</div>

<div class="molecule-description">
    Nasal glucagon is a biologic entity being studied for the treatment of severe hypoglycemia in people with diabetes treated with insulin.
    <br/><br>
    For more information on nasal glucagon clinical studies, click
    <a href="https://clinicaltrials.gov/ct2/results?term=Nasal+Glucagon&Search=Search" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<div>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137474">Lilly Acquires Phase III Intranasal Glucagon From Locemia Solutions</a>—October 9, 2015</div>
<p></p>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-37").bind('click', function() {
    $("#content-37").bPopup();
    return false;
});
</script>
</li>
<li id='cell-38' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-38" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
    <div class="molecule-inner-content">
        <label>*BACE - AZD3293
        </br>
        Alzheimer's
    </label>
    <label class="toolt">New Molecular Entity</label>
    <label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-38">
<div class="molecule-title">

<div class="mtitle DINBold">AZD3293</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Bio-Medicines</label>
</div>
</div>

<div class="molecule-description">
LY3314814 (AZD 3293), a chemical entity, is an oral beta secretase cleaving enzyme (BACE) inhibitor. LY3314814 is being studied for the treatment of Alzheimer's disease.<br/><br>
For more information on BACE - AZD3293 clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=AZD3293+&Search=Search" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>PRESS RELEASES (1/1/2010-7/19/2016)</h1>
<p>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137531">Eli Lilly And Company And AstraZeneca Announce Continuation Of Pivotal Clinical Trial For People With Early Alzheimer's Disease</a>
- April 8, 2016</p>
<p></p>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-38").bind('click', function() {
    $("#content-38").bPopup();
    return false;
});
</script>
</li>
<li id='cell-39' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-39" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Galcanezumab
<br>
cluster
<br>
headache</label>
<label class="toolt">New Molecular Entity
</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-39">
<div class="molecule-title">

<div class="mtitle DINBold">Galcanezumab
<br>
cluster headache</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
LY2951742 (galcanezumab), a CGRP monoclonal antibody, is a biologic entity that binds and inhibits the activity of calcitonin gene related peptide (CGRP). LY2951742 is being studied for the prevention of cluster headache and migraine.
<br/><br>
For more information on galcanezumab clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2951742" target="_blank">here</A>.</u>
</a><br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p><br/>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<p>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137444">Lilly's Investigational Medicine for Prevention of Migraine Met Primary Endpoint in a Phase 2b Study</a>
– June 17, 2015<br/><br/>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137274">Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics</a>
– January 13, 2014</p>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-39").bind('click', function() {
    $("#content-39").bPopup();
    return false;
});
</script>
</li>
<li id='cell-40' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-40" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Solanezumab<br>Alzheimer's</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-40">
<div class="molecule-title">

<div class="mtitle DINBold">Solanezumab (soe" la nez' ue mab)
</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Bio-Medicines</label>
</div>
</div>

<div class="molecule-description">
LY2062430 (solanezumab) is a biologic entity that binds to soluble monomeric forms of amyloid ß (Ab) after it is produced. LY2062430 is being studied for its potential to slow the progression of Alzheimer's disease.
<br/><br>
For more information on solanezumab clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2062430" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<p>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137526">Lilly Announces Change To Primary Endpoint Of EXPEDITION3 Study</a>—March 15, 2016<br/><br/>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137458">Lilly To End Contract With The University Of California, San Diego For A4 Alzheimer's Study</a>—August 4, 2015<br/><br/>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137452">Data Using New Delayed-Start Methodology Suggested Benefit Of Early Treatment With Solanezumab In Patients With Mild Alzheimer's Disease</a>—July 22, 2015<br/><br/>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137336">New Data Shows Cognitive Impairment Precedes And Predicts Subsequent Functional Impairment In Patients With Mild Alzheimer's Disease</a>—July 15, 2014<br/><br/>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137332">Lilly To Showcase Data From Its Alzheimer's Disease Portfolio At The Alzheimer's Association International Conference 2014 (AAIC 2014)</a>—July 8, 2014<br/><br/>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137222" target="_blank">Lilly to Host Conference Call to Discuss Trial Design of New Solanezumab Phase 3 Study</a>
– July 3, 2013<br/><br/>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=136187" target="_blank">Lilly Provides Update on Next Steps for Solanezumab</a>—December 12, 2012<br/><br/>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=134212" target="_blank">Lilly Announces Detailed Results of the Phase 3 Solanezumab EXPEDITION Studies Following a Presentation of the Independent Analyses by the Alzheimer's Disease Cooperative Study (ADCS)</a>—October 8, 2012<br/><br/>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=132129" target="_blank">Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease</a>—August 24, 2012</p>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-40").bind('click', function() {
    $("#content-40").bPopup();
    return false;
});
</script>
</li>
<li id='cell-41' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-41" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>*Tanezumab
<br>osteoarthritic<br>
pain</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-41">
<div class="molecule-title">

<div class="mtitle DINBold">Tanezumab (ta nez' oo mab)</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Bio-Medicines</label>
</div>
</div>

<div class="molecule-description">
Tanezumab, a biologic entity, is a humanized monoclonal antibody that inhibits nerve growth factor. Tanezumab is being studied in collaboration with Pfizer for the treatment of multiple pain indications including osteoarthritis pain.<br/><br/>
For more information on tanezumab clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=tanezumab" target="_blank">here</a>.<br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<p>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137402">Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab</a>
– March 23, 2015</p>
<p></p>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-41").bind('click', function() {
    $("#content-41").bPopup();
    return false;
});
</script>
</li>
<li id='cell-42' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-42" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Abemaciclib<br>
metastatic breast
</br>
cancer</label>
<label class="toolt">NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-42">
<div class="molecule-title">

<div class="mtitle DINBold">Abemaciclib (a be muh sī klib)</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LLY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is
being studied for the treatment of metastatic breast cancer.
<br/><br>
For more information on LY2835219 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2835219" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<span style="color: #000000;">
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</span>
</h1>
<p>
<span style="color: #000000;">
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137570">
<span style="color: #000000;">Lilly And Boehringer Ingelheim Announce Clinical Trial Collaboration In Metastatic Breast Cancer</span>
</a>—July 13, 2016<br/><br/></span>
</p>
<p>
<span style="color: #000000;">
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137549">
<span style="color: #000000;">Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy</span>
</a>—June 3, 2016<br/><br/></span>
</p>
<p>
<span style="color: #000000;">
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137547">
<span style="color: #000000;">Lilly Announces Webcast To Discuss Abemaciclib Data</span>
</a>—May 31, 2016<br/><br/></span>
</p>
<p>
<span style="color: #000000;">
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137540">
<span style="color: #000000;">ASCO Data Underscore Lilly's Diverse Oncology Pipeline And Portfolio</span>
</a>—May 18, 2016<br/><br/></span>
</p>
<p>
<span style="color: #000000;">
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137472">
<span style="color: #000000;">Lilly Receives FDA Breakthrough Therapy Designation For Abemaciclib - A CDK 4 And 6 Inhibitor - In Advanced Breast Cancer</span>
</a>—October 8, 2015<br/><br/></span>
</p>
<p>
<span style="color: #000000;">
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137407">
<span style="color: #000000;">Lilly Releases Early-Stage Pipeline Data At AACR Annual Meeting 2015</span>
</a>—April 20, 2015<br/><br/></span>
</p>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-42").bind('click', function() {
    $("#content-42").bPopup();
    return false;
});
</script>
</li>
<li id='cell-43' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-43" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>*Empagliflozin
<br>type 1
<br>diabetes</label>
<label class="toolt">NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-43">
<div class="molecule-title">

<div class="mtitle DINBold">Empagliflozin</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Diabetes</label>
</div>
</div>

<div class="molecule-description">
BI10773 (Empagliflozin) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for type 1 diabetes.
<br/><br>
For more information on BI10773 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=BI10773" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<p>None during this time period.<br/><br/></p>
<h1>
<strong></strong>
</h1>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-43").bind('click', function() {
    $("#content-43").bPopup();
    return false;
});
</script>
</li>
<li id='cell-44' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-44" class=" nilex_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/achived_milestone_molecule.png" alt=""/>
<div class="molecule-inner-content">
<label>Ixekizumab axial spondyloarthritis</label>
<label class="toolt">Select NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-44">
<div class="molecule-title">

<div class="minfobg"><img src="./img/achived_milestone_molecule.png" alt=""/></div>

<div class="mtitle DINBold">Ixekizumab axial spondyloarthritis</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Bio-Medicines</label>
<label style='display:block;'>Molecule That Achieved Milestone
</label>
</div>
</div>

<div class="molecule-description">
LY2439821 (ixekizumab) is a biologic entity that neutralizes a soluble factor called interleukin-17A (IL-17). LY2439821 is being studied for the treatment of axial spondyloarthritis.
<br/><br>
For more information on ixekizumab clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=LY2439821" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p><br/>
<br/><br/>
<h1 style="text-align: left;">
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<p style="text-align: left;">None during this time period.</p>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-44").bind('click', function() {
    $("#content-44").bPopup();
    return false;
});
</script>
</li>
<li id='cell-45' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-45" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Galcanezumab<br>migraine prevention</label>
<label class="toolt">Select NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-45">
<div class="molecule-title">

<div class="mtitle DINBold">Galcanezumab<br>migraine prevention</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
LY2951742 (galcanezumab), a CGRP monoclonal antibody, is a biologic entity that binds and inhibits the activity of calcitonin gene related peptide (CGRP). LY2951742 is being studied for the prevention of both chronic and episodic migraine.
<br/><br>
For more information on galcanezumab clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2951742" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p><br/>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<div>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137444">Lilly's Investigational Medicine for Prevention of Migraine Met Primary Endpoint in a Phase 2b Study</a>
– June 17, 2015</div>
<br/>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137274">Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics</a>
– January 13, 2014
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-45").bind('click', function() {
    $("#content-45").bPopup();
    return false;
});
</script>
</li>

<li id='cell-45' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-45" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Solanezumab<br>preclinical AD</label>
<label class="toolt">NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-45">
<div class="molecule-title">

<div class="mtitle DINBold">Solanezumab (soe" la nez' ue mab)
</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Bio-Medicines</label>
</div>
</div>

<div class="molecule-description">
LY2062430 (solanezumab) is a biologic entity that binds to soluble monomeric forms of amyloid ß (Ab) after it is produced. LY2062430 is being studied for its potential to slow the progression of Alzheimer's disease.
<br/><br>
For more information on solanezumab clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2062430" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<div>
None during this time period.</div>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-45").bind('click', function() {
    $("#content-45").bPopup();
    return false;
});
</script>
</li>
<li id='cell-46' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-46" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>*Tanezumab<br>cancer pain</label>
<label class="toolt">NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-46">
<div class="molecule-title">

<div class="mtitle DINBold">Tanezumab (ta nez' oo mab)</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Bio-Medicines</label>
</div>
</div>

<div class="molecule-description">
Tanezumab, a biologic entity, is a humanized monoclonal antibody that inhibits nerve growth factor. Tanezumab is being studied in collaboration with Pfizer for the treatment of cancer pain.<br/><br/>
For more information on tanezumab clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=tanezumab" target="_blank">here</a>.<br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-4/19/2016)</h1>
<div>None during this time period.</div>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-46").bind('click', function() {
    $("#content-46").bPopup();
    return false;
});
</script>
</li>
<li id='cell-47' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-47" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>*Tanezumab chronic lower<br>back pain</label>
<label class="toolt">NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-47">
<div class="molecule-title">

<div class="mtitle DINBold">Tanezumab (ta nez' oo mab)</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Bio-Medicines</label>
</div>
</div>

<div class="molecule-description">
Tanezumab, a biologic entity, is a humanized monoclonal antibody that inhibits nerve growth factor. Tanezumab is being studied in collaboration with Pfizer for the treatment of chronic lower back pain.<br/><br/>
For more information on tanezumab clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=tanezumab" target="_blank">here</a>.<br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<div>None during this time period.</div>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-47").bind('click', function() {
    $("#content-47").bPopup();
    return false;
});
</script>
</li>
<li id='cell-48' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-48" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Abemaciclib
<br>
lung cancer</label>
<label class="toolt">NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-48">
<div class="molecule-title">

<div class="mtitle DINBold">Abemaciclib (a be muh sī klib)</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is
being studied for the treatment of KRAS mutant non small cell lung cancer.
<br/><br>
For more information on abemaciclib clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2835219" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<p>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137407">Lilly Releases Early-Stage Pipeline Data At AACR Annual Meeting 2015</a>—April 20, 2015<br/><br/>
<a href="https://investor.lilly.com/releasedetail.cfm?ReleaseID=848054">Abemaciclib - Lilly's Oral CDK 4/6 Inhibitor - Shows Single-Agent Activity In A Phase I Study For Patients With A Specific Type Of Lung Cancer</a>
– May 12, 2014</p>
<p></p>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-48").bind('click', function() {
    $("#content-48").bPopup();
    return false;
});
</script>
</li>
<li id='cell-49' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-49" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Ramucirumab<br>bladder cancer</label>
<label class="toolt">NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-49">
<div class="molecule-title">

<div class="mtitle DINBold">Ramucirumab (ra" mue sir' ue mab)</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY3009806 (ramucirumab), a biologic entity, is an antiangiogenic therapy. Specifically, it is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF
receptor ligands VEGF-A, VEGF-C, and VEGF-D. LY3009806 is currently being studied for the treatment of second-line bladder cancer.
<br/><br>
For more information on ramucirumab clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY3009806" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137466">Lilly's CYRAMZA® (Ramucirumab) Significantly Improves Progression-Free Survival In Phase II Bladder Cancer Trial</a>—September 28, 2015<br/><br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-49").bind('click', function() {
    $("#content-49").bPopup();
    return false;
});
</script>
</li>
<li id='cell-50' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-50" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Ramucirumab
<br>
gastric cancer</label>
<label class="toolt">NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-50">
<div class="molecule-title">

<div class="mtitle DINBold">Ramucirumab (ra" mue sir' ue mab)</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY3009806 (ramucirumab), a biologic entity, is an antiangiogenic therapy. Specifically, it is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF
receptor ligands VEGF-A, VEGF-C, and VEGF-D. LY3009806 is currently being studied for the treatment of first-line gastric cancer.
<br/><br>
For more information on ramucirumab clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY3009806" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<div>
<p>
<span style="color: #000000;">
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137540">
<span style="color: #000000;">ASCO Data Underscore Lilly's Diverse Oncology Pipeline And Portfolio</span>
</a>—May 18, 2016<br/><br/></span>
</p>
<span style="color: #000000;">
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137422">
<span style="color: #000000;">Lilly To Present CYRAMZA® (Ramucirumab) Data At 2015 ASCO Annual Meeting</span>
</a>—May 28, 2015</span><br/><br/><br/></div>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-50").bind('click', function() {
    $("#content-50").bPopup();
    return false;
});
</script>
</li>
<li id='cell-51' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-51" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Ramucirumab hepatocellular cancer</label>
<label class="toolt">NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-51">
<div class="molecule-title">

<div class="mtitle DINBold">Ramucirumab (ra" mue sir' ue mab)</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY3009806 (ramucirumab), a biologic entity, is an antiangiogenic therapy. Specifically, it is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF
receptor ligands VEGF-A, VEGF-C, and VEGF-D. LY3009806 is currently being studied for the treatment of 2nd line hepatocellular carcinoma.
<br/><br/>
For more information on baricitinib clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=LY3009806+hepatocellular&Search=Search" target="_blank">here</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<div>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137319">Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial</a>—June 11, 2014<br/><br/><br/></div>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-51").bind('click', function() {
    $("#content-51").bPopup();
    return false;
});
</script>
</li>
<li id='cell-52' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-52" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Ramucirumab<br>NSCLC</label>
<label class="toolt">NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-52">
<div class="molecule-title">

<div class="mtitle DINBold">Ramucirumab (ra" mue sir' ue mab)</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY3009806 (ramucirumab), a biologic entity, is an antiangiogenic therapy. Specifically, it is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF
receptor ligands VEGF-A, VEGF-C, and VEGF-D. LY3009806 is currently being studied for the treatment of first-line, EGFR positive NSCLC.
<br/><br>
For more information on ramucirumab clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY3009806" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
<p></p>
<p>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137550">Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer</a>—June 5, 2016</p>
<p>
<span style="color: #000000;" data-mce-mark="1">
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137540">
<span style="color: #000000;" data-mce-mark="1"><br/>ASCO Data Underscore Lilly's Diverse Oncology Pipeline And Portfolio</span>
</a>—May 18, 2016</span><br/><br/></p>
<span style="color: #000000;">
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137422">
<span style="color: #000000;">Lilly To Present CYRAMZA® (Ramucirumab) Data At 2015 ASCO Annual Meeting</span>
</a>—May 28, 2015</span><br/><br/>
<span style="color: #000000;">
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137426">
<span style="color: #000000;">Lilly, Merck Enter Collaboration Agreement To Research Immuno-Oncology Combination Regimens In Multiple Types Of Cancer</span>
</a>—January 13, 2015</span>
<p>
<span style="color: #000000;" data-mce-mark="1"></span>
</p>
<p></p>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-52").bind('click', function() {
    $("#content-52").bPopup();
    return false;
});
</script>
</li>
<li id='cell-54' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-54" class=" diagnostic_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/scientific_name_given.png" alt=""/>
<div class="molecule-inner-content">
<label>Flortaucipir F 18</label>
<label class="toolt">Diagnostic</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-54">
<div class="molecule-title">
<div class="minfobg"><img src="./img/scientific_name_given.png" alt=""/></div>
<div class="mtitle DINBold">Flortaucipir F 18 (flor tau’ si pir)</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Research</label>
<label style='display:block;'>Nonproprietary Name Granted</label>
</div>
</div>

<div class="molecule-description">
18F-AV-1451 (Flortaucipir F 18) is a chemical entity PET imaging agent being studied for the imaging of Tau pathology.<br/><br>
For more information on Flortaucipir F 18 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=18F-AV-1451" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>

<br/><br/>
<div>
<h1>
<strong>PRESS RELEASES</strong>
(1/1/2010-7/19/2016)</h1>
</div>
<a href="http://lilly.mediaroom.com/index.php?s=9042&item=137332">Lilly To Showcase Data From Its Alzheimer's Disease Portfolio At The Alzheimer's Association International Conference 2014 (AAIC 2014)</a>—July 8, 2014<br/><br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-54").bind('click', function() {
    $("#content-54").bPopup();
    return false;
});
</script>
</li>
</ul>
</div>
</div>

<div class="cells-container">
<div class="cells-container-inner">
<h1 class="toggle active">
<label class="exp_open"></label>
<span>Phase II</span>
</h1>
<ul class="molecule-container">
<li id='cell-55' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-55" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>IL-23 MAb ulcerative<br>colitis</label>
<label class="toolt">New Molecular Entity
</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-55">
<div class="molecule-title">

<div class="mtitle DINBold">IL-23 antibody</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
LY3074828 (IL-23 antibody) is a biologic entity that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of ulcerative colitis.
<br/><br/>
For more information on LY3074828 clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=LY3074828&Search=Search" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-55").bind('click', function() {
    $("#content-55").bPopup();
    return false;
});
</script>
</li>
<li id='cell-56' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-56" class=" nme_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/lost_molecule.png" alt=""/>
<div class="molecule-inner-content">
<label>BMP-6 MAb<br>anemia</label>
<label class="toolt">New Molecular Entity
</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-56">
<div class="molecule-title">

<div class="minfobg"><img src="./img/lost_molecule.png" alt=""/></div>

<div class="mtitle DINBold">BMP-6 MAb anemia</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Research</label>
<label style='display:block;'>Lost Through Attrition</label>
</div>
</div>

<div class="molecule-description">
LY3113593 (BMP-6 antibody) is a fully humanized antibody that binds to the bone morphogenetic protein-6 and inhibits its activity. LY3113593 is being studied for the treatment of anemia. For more information on LY3113593 clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=LY3113593&Search=Search" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-56").bind('click', function() {
    $("#content-56").bPopup();
    return false;
});
</script>
</li>
<li id='cell-57' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-57" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>PCSK9 MAb
<br>CV disease</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-57">
<div class="molecule-title">

<div class="mtitle DINBold">PCSK9 Monoclonal Antibody</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
LY3015014 (PCSK9 monoclonal antibody) is a biologic entity that binds to and inhibits the activity of proprotein convertase subtilisin/kexin type 9. LY3015014 is being studied for the treatment of cardiovascular disease.
<br/><br>
For more information on LY3015014 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY3015014" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p <br /><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-57").bind('click', function() {
    $("#content-57").bPopup();
    return false;
});
</script>
</li>
<li id='cell-58' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-58" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Ultra Rapid Insulin
<br>
diabetes</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-58">
<div class="molecule-title">

<div class="mtitle DINBold">Ultra Rapid Insulin</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
URI is pursued pre-FRD through two approaches, BioChaperone insulin lispro in collaboration with Adocia and an internal ultra-rapid formulation project of insulin lispro. Both projects are biologic entities being studied for the treatment of type 1
and type 2 diabetes.<br/><br>
For more information on BioChaperone Lispro clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=BioChaperone+Insulin+Lispro+&Search=Search" target="_blank">here</a>.

<br/><br>NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-58").bind('click', function() {
    $("#content-58").bPopup();
    return false;
});
</script>
</li>
<li id='cell-59' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-59" class=" nme_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/lost_molecule.png" alt=""/>
<div class="molecule-inner-content">
<label>Myostatin MAb
<br>disuse atrophy</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-59">
<div class="molecule-title">

<div class="minfobg"><img src="./img/lost_molecule.png" alt=""/></div>

<div class="mtitle DINBold">Myostatin Monoclonal Antibody</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Research</label>
<label style='display:block;'>Lost Through Attrition</label>
</div>
</div>

<div class="molecule-description">
LY2495655 (myostatin monoclonal antibody), a biologic entity, is a fully humanized antibody that inhibits myostatin activity. LY2495655 is being studied for the treatment of disuse muscle atrophy.
<br/><br>
For more information on LY2495655 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2495655" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-59").bind('click', function() {
    $("#content-59").bPopup();
    return false;
});
</script>
</li>
<li id='cell-60' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-60" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Edivoxetine
<br>CNS disorder</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-60">
<div class="molecule-title">

<div class="mtitle DINBold">Edivoxetine (e" di vox' e teen hye" droe klor' ide)
</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Bio-Medicines</label>
</div>
</div>

<div class="molecule-description">
LY2216684 (edivoxetine) is a chemical entity that inhibits the reuptake of norepinephrine. LY2216684 is being studied for multiple CNS disorders. Molecule is owned by a 3rd party, Lilly retains rights.
<br/><br>
For more information on edivoxetine clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2216684" target="_blank">here</a>.<br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-60").bind('click', function() {
    $("#content-60").bPopup();
    return false;
});
</script>
</li>
<li id='cell-61' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-61" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Prexasertib<br>cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-61">
<div class="molecule-title">

<div class="mtitle DINBold">Prexasertib (prex” a ser’ tib)</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY2606368 monomesylate monohydrate (formerly known as Chk1 inhibitor) is a chemical entity that preferentially binds to and inhibits checkpoint kinase 1 (Chk1), a global regulator of the mammalian cell cycle and, to a lesser extent, inhibits Chk2.
LY2606368 monomesylate monohydrate is being studied for the treatment of cancer.<br/><br>
For more information on LY2606368 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2606368" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-61").bind('click', function() {
    $("#content-61").bPopup();
    return false;
});
</script>
</li>
<li id='cell-62' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-62" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>CXCR4 pept antag<br>
cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-62">
<div class="molecule-title">

<div class="mtitle DINBold">CXCR4 Peptide Antagonist</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY2510924 (CXCR4 peptide antagonist) is a biologic entity that antagonizes ligand binding to the CXC chemokine receptor 4. LY2510924 is being studied for the treatment of cancer.<br/><br>
For more information on LY2510924 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2510924" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-62").bind('click', function() {
    $("#content-62").bPopup();
    return false;
});
</script>
</li>
<li id='cell-63' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-63" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Emibetuzumab<br>cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-63">
<div class="molecule-title">

<div class="mtitle DINBold">Emibetuzumab (em” i be tooz’ ue mab)</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY2875358 (formerly known as c-Met antibody), a biologic entity, was designed as a bivalent c-Met antibody that has neutralization and internalization activity with minimal agonistic activity. LY2875358 is being studied for the treatment of NSCLC.
<br/><br>
For more information on LY2875358 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2875358" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-63").bind('click', function() {
    $("#content-63").bPopup();
    return false;
});
</script>
</li>
<li id='cell-64' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-64" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>FGF receptor inh
<br>
cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-64">
<div class="molecule-title">

<div class="mtitle DINBold">FGF Receptor Inhibitor</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY2874455 (FGF receptor inhibitor), a chemical entity, inhibits autophosphorylation of fibroblast growth factor (FGF) receptors 1, 2, 3 and 4, which is required for activation of FGF-induced downstream signaling. LY2874455 is being studied for the
treatment of cancer.<br/><br>
For more information on LY2874455 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2874455" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-64").bind('click', function() {
    $("#content-64").bPopup();
    return false;
});
</script>
</li>
<li id='cell-65' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-65" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Galunisertib<br>cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-65">
<div class="molecule-title">

<div class="mtitle DINBold">Galunisertib (gal ue” ni ser’ tib)</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY2157299 monohydrate (formerly known as TGFb R1 kinase inhibitor) is a chemical entity that selectively blocks transforming growth factor-β receptor I kinase and TGF-b signaling. LY2157299 monohydrate is being studied for the treatment of pancreatic
and hepatocellular cancer.
<br/><br>
For more information on LY2157299 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2157299" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-65").bind('click', function() {
    $("#content-65").bPopup();
    return false;
});
</script>
</li>
<li id='cell-66' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-66" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Merestinib
<br>
cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-66">
<div class="molecule-title">

<div class="mtitle DINBold">Merestinib cancer (mer es’ ti nib)</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY2801653 (formerly known as c-Met inhibitor) is a chemical entity that has been shown in vitro to be a reversible type II ATP-competitive inhibitor of MET, a receptor for hepatocyte growth factor. Preclinical testing also has shown LY2801653 to
inhibit several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, and DDR1/2 and the serine/threonine kinases MKNK1/2. LY2801653 is being studied for the treatment of cancer.
<br/><br>
For more information on LY2801653 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2801653" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-66").bind('click', function() {
    $("#content-66").bPopup();
    return false;
});
</script>
</li>
<li id='cell-67' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-67" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>NOTCH inhibitor<br>
cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-67">
<div class="molecule-title">

<div class="mtitle DINBold">NOTCH inhibitor cancer</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY3039478 (NOTCH Inhibitor) is a new chemical entity being studied for the treatment of cancer.<br/><br>
For more information on LY3039478 clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=LY3039478&Search=Search" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-67").bind('click', function() {
    $("#content-67").bPopup();
    return false;
});
</script>
</li>
<li id='cell-68' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-68" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>PI3 kinase/<br>mTOR dual inh<br>cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-68">
<div class="molecule-title">

<div class="mtitle DINBold">PI3 Kinase/mTOR Dual Inhibitor</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY3023414 (PI3 Kinase/mTOR dual Inhibitor) is a chemical entity being studied for the treatment of prostate cancer and NSCLC.
<br/><br>
For more information on LY3023414 clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=LY3023414&Search=Search" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-68").bind('click', function() {
    $("#content-68").bPopup();
    return false;
});
</script>
</li>
<li id='cell-69' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-69" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Ralimetinib
<br>cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-69">
<div class="molecule-title">

<div class="mtitle DINBold">Ralimetinib (ral’’ i me’ ti nib)</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY2228820 dimesylate (formerly known as p38 MAP kinase inhibitor) is a chemical entity that preferentially binds to and inhibits p38 MAP kinase. LY2228820 dimesylate is being studied for the treatment of ovarian cancer.<br/><br>
For more information on LY2228820 dimesylate clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=LY2228820" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>

<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-69").bind('click', function() {
    $("#content-69").bPopup();
    return false;
});
</script>
</li>
<li id='cell-70' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-70" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Baricitinib<br>atopic dermatitis</label>
<label class="toolt">Select NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-70">
<div class="molecule-title">

<div class="mtitle DINBold">Baricitinib
<br>
atopic dermatitis</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Bio-Medicines</label>
</div>
</div>

<div class="molecule-description">
LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of atopic dermatitis.
<br/><br>
For more information on LY3009104 clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=LY3009104" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-70").bind('click', function() {
    $("#content-70").bPopup();
    return false;
});
</script>
</li>
<li id='cell-71' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-71" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Baricitinib<br>systemic lupus erythematosus</label>
<label class="toolt">Select NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-71">
<div class="molecule-title">

<div class="mtitle DINBold">Baricitinib<br>systemic lupus erythematosus</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Bio-Medicines</label>
</div>
</div>

<div class="molecule-description">
LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of systemic lupus erythematosus.
<br/><br>
For more information on LY3009104 clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=LY3009104" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-71").bind('click', function() {
    $("#content-71").bPopup();
    return false;
});
</script>
</li>
<li id='cell-72' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-72" class=" nilex_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/lost_molecule.png" alt=""/>
<div class="molecule-inner-content">
<label>Baricitinib
<br>
psoriasis</label>
<label class="toolt">Select NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-72">
<div class="molecule-title">

<div class="minfobg"><img src="./img/lost_molecule.png" alt=""/></div>

<div class="mtitle DINBold">Baricitinib
<br>
psoriasis</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Bio-Medicines</label>
<label style='display:block;'>Lost Through Attrition</label>
</div>
</div>

<div class="molecule-description">
LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of psoriasis.

<br/><br>
For more information on LY3009104 clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=LY3009104" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-72").bind('click', function() {
    $("#content-72").bPopup();
    return false;
});
</script>
</li>
<li id='cell-73' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-73" class=" nilex_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Abemaciclib<br>squamous NSCLC</label>
<label class="toolt">NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-73">
<div class="molecule-title">

<div class="mtitle DINBold">Abemaciclib (a be muh sī klib)</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is
being studied for the treatment of squamous NSCLC.

<br/><br>
For more information on LY2835219 clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=LY2835219&Search=Search" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-73").bind('click', function() {
    $("#content-73").bPopup();
    return false;
});
</script>
</li>
<li id='cell-75' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-75" class=" nilex_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/lost_molecule.png" alt=""/>
<div class="molecule-inner-content">
<label>Baricitinib
<br>
diabetic nephropathy</label>
<label class="toolt">Select NILEX</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-75">
<div class="molecule-title">

<div class="minfobg"><img src="./img/lost_molecule.png" alt=""/></div>

<div class="mtitle DINBold">Baricitinib
<br>
diabetic nephropathy</div>
<div class="molecule-position">
<label>Phase III</label>
<label>Business area: Bio-Medicines</label>
<label style='display:block;'>Lost Through Attrition</label>
</div>
</div>

<div class="molecule-description">
LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of diabetic nephropathy.

<br/><br>
For more information on LY3009104 clinical studies, click
<a href="https://clinicaltrials.gov/ct2/results?term=LY3009104" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-54").bind('click', function() {
    $("#content-54").bPopup();
    return false;
});
</script>
</li>
<li id='cell-74' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-74" class=" diagnostic_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Florbenazine</label>
<label class="toolt">Diagnostic</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-74">
<div class="molecule-title">

<div class="mtitle DINBold">Florbenazine (flor ben' a zeen)</div>
<div class="molecule-position">
<label>Phase II</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
Florbenazine (18F-AV-133) is a chemical entity PET imaging agent being studied for the imaging of Parkinson's disease pathology.
<br/><br>
For more information on 18F-AV-133 clinical studies, click
<a href="http://clinicaltrials.gov/ct2/results?term=AV-133&Search=Search" target="_blank">here</A>.</u>
</a><br/>
<br>
<p style="font-size:10px;">
NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.</p>

<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-74").bind('click', function() {
    $("#content-74").bPopup();
    return false;
});
</script>
</li>
<li id='cell-76' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-77' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-78' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-79' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-80' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-81' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-82' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-83' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-84' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-85' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-86' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-87' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-88' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-89' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-90' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
</ul>
</div>
</div>

<div class="cells-container">
<div class="cells-container-inner">
<h1 class="toggle active">
<label class="exp_open"></label>
<span>Phase I</span>
</h1>
<ul class="molecule-container">
<li id='cell-91' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-91" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>diabetes</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-91">
<div class="molecule-title">

<div class="mtitle DINBold">diabetes</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
New chemical entity. Molecule is owned by a 3rd party, Lilly retains rights.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-91").bind('click', function() {
    $("#content-91").bPopup();
    return false;
});
</script>
</li>
<li id='cell-92' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-92" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>DGAT-2 inhibitor dyslipidemia</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-92">
<div class="molecule-title">

<div class="mtitle DINBold">DGAT-2 inhibitor dyslipidemia</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
"DGAT-2 inhibitor" is a new chemical entity being studied for the treatment of dyslipidemia.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-92").bind('click', function() {
    $("#content-92").bPopup();
    return false;
});
</script>
</li>
<li id='cell-93' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-93" class=" nme_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/achived_milestone_molecule.png" alt=""/>
<div class="molecule-inner-content">
<label>GIP/GLP-1
<br>
Co-agonist
<br>
Peptide diabetes</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-93">
<div class="molecule-title">

<div class="minfobg"><img src="./img/achived_milestone_molecule.png" alt=""/></div>

<div class="mtitle DINBold">GIP/GLP-1 Co-agonist Peptide</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
<label style='display:block;'>Molecule That Achieved Milestone
</label>
</div>
</div>

<div class="molecule-description">
"GIP/GLP-1 Co-agonist Peptide" is a new biologic entity being studied for the treatment of diabetes.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-93").bind('click', function() {
    $("#content-93").bPopup();
    return false;
});
</script>
</li>
<li id='cell-94' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-94" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>hypoglycemia</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-94">
<div class="molecule-title">

<div class="mtitle DINBold">hypoglycemia</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
New biologic entity.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-94").bind('click', function() {
    $("#content-94").bPopup();
    return false;
});
</script>
</li>
<li id='cell-95' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-95" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Blosozumab
<br>
osteoporosis</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-95">
<div class="molecule-title">

<div class="mtitle DINBold">Blosozumab (bloe soz' ue mab)</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
LY2541546 (blosozumab) is a new biologic entity that binds and neutralizes sclerostin. LY2541546 is being studied as a treatment for osteoporosis.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-95").bind('click', function() {
    $("#content-95").bPopup();
    return false;
});
</script>
</li>
<li id='cell-96' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-96" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>BAFF/IL-17<br>Bispecific<br>immunology
</label>
<label class="toolt">New Molecular Entity.</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-96">
<div class="molecule-title">

<div class="mtitle DINBold">BAFF/IL-17 Bispecific Antibody</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
"BAFF/IL-17 Bispecific Antibody" is a new biologic entity being studied for the treatment of immune diseases.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-96").bind('click', function() {
    $("#content-96").bPopup();
    return false;
});
</script>
</li>
<li id='cell-97' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-97" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>BTK inhibitor<br>immunology</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-97">
<div class="molecule-title">

<div class="mtitle DINBold">BTK inhibitor</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
"BTK inhibitor" is a new chemical entity being studied for the treatment of immune diseases.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-97").bind('click', function() {
    $("#content-97").bPopup();
    return false;
});
</script>
</li>
<li id='cell-98' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-98" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>CXCR1/2<br>Ligands MAb<br>immunology
</label>
<label class="toolt">New Molecular Entity.</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-98">
<div class="molecule-title">

<div class="mtitle DINBold">CXCR1/2 Ligands Antibody</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
"CXCR1/2 Ligands Antibody" is a new biologic entity being studied for the treatment of immune diseases.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-98").bind('click', function() {
    $("#content-98").bPopup();
    return false;
});
</script>
</li>
<li id='cell-99' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-99" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>IL-21 MAb immunology</label>
<label class="toolt">New Molecular Entity.</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-99">
<div class="molecule-title">

<div class="mtitle DINBold">IL-21 Antibody</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
"IL-21 Antibody" is a new biologic entity being studied for the treatment of immune diseases.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-99").bind('click', function() {
    $("#content-99").bPopup();
    return false;
});
</script>
</li>
<li id='cell-100' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-100" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>A ß antibody Fab<br>PEG<br>Alzheimer's</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-100">
<div class="molecule-title">

<div class="mtitle DINBold">A ß antibody Fab PEG Alzheimer's</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
"A b Antibody Fab PEG" is a new biologic entity being studied for the treatment of Alzheimer's disease.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-100").bind('click', function() {
    $("#content-100").bPopup();
    return false;
});
</script>
</li>
<li id='cell-101' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-101" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>BACE inhibitor
<br/>
Alzheimer’s</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-101">
<div class="molecule-title">

<div class="mtitle DINBold">BACE inhibitor Alzheimer's</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
"BACE Inhibitor" is a new chemical entity being studied for the treatment of Alzheimer's disease.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-101").bind('click', function() {
    $("#content-101").bPopup();
    return false;
});
</script>
</li>
<li id='cell-102' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-102" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>D1 potentiator dementia
</label>
<label class="toolt">New Molecular Entity.</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-102">
<div class="molecule-title">

<div class="mtitle DINBold">D1 potentiator</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
"D1 potentiator" is a new chemical entity being studied for the treatment of dementia.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-102").bind('click', function() {
    $("#content-102").bPopup();
    return false;
});
</script>
</li>
<li id='cell-103' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-103" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>N3pG-Aß MAb
<br>
Alzheimer's
<br>
disease</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-103">
<div class="molecule-title">

<div class="mtitle DINBold">N3pG-Aß Monoclonal Antibody</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
"N3pG-Aß Monoclonal Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-103").bind('click', function() {
    $("#content-103").bPopup();
    return false;
});
</script>
</li>
<li id='cell-104' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-104" class=" nme_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/achived_milestone_molecule.png" alt=""/>
<div class="molecule-inner-content">
<label>Tau MAb
<br>
Alzheimer's</label>
<label class="toolt">New Molecular Entity
</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-104">
<div class="molecule-title">

<div class="minfobg"><img src="./img/achived_milestone_molecule.png" alt=""/></div>

<div class="mtitle DINBold">Tau Antibody</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
<label style='display:block;'>Molecule That Achieved Milestone
</label>
</div>
</div>

<div class="molecule-description">
"Tau Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-104").bind('click', function() {
    $("#content-104").bPopup();
    return false;
});
</script>
</li>
<li id='cell-105' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-105" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Pomaglumetad methionil<br>schizophrenia</label>
<label class="toolt">New molecular entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-105">
<div class="molecule-title">

<div class="mtitle DINBold">Pomaglumetad methionil</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
LY2140023 monohydrate (pomaglumetad methionil) is a chemical entity agonist of the metabotropic glutamate 2/3 receptors. LY2140023 licensed to Denovo Biopharma to identify genetic biomarkers and to screen for appropriate patient subsets for further
study in future clinical trials.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-105").bind('click', function() {
    $("#content-105").bPopup();
    return false;
});
</script>
</li>
<li id='cell-106' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-106" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Angiopoietin 2<br>MAb<br>cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-106">
<div class="molecule-title">

<div class="mtitle DINBold">Angiopoietin 2 MAb cancer</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Research</label>
</div>
</div>

<div class="molecule-description">
"Angiopoietin 2 Antibody" is a new biologic entity being studied for the treatment of cancer.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-106").bind('click', function() {
    $("#content-106").bPopup();
    return false;
});
</script>
</li>
<li id='cell-107' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-107" class=" nme_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/achived_milestone_molecule.png" alt=""/>
<div class="molecule-inner-content">
<label>Chk1 inhibitor cancer</label>
<label class="toolt">New Molecular Entity
</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-107">
<div class="molecule-title">

<div class="minfobg"><img src="./img/achived_milestone_molecule.png" alt=""/></div>

<div class="mtitle DINBold">Chk1 Inhibitor</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Oncology</label>
<label style='display:block;'>Molecule That Achieved Milestone
</label>
</div>
</div>

<div class="molecule-description">
"Chk1 Inhibitor" is a new chemical entity being studied for the treatment of cancer. Molecule is owned by a 3rd party, Lilly retains rights.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-107").bind('click', function() {
    $("#content-107").bPopup();
    return false;
});
</script>
</li>
<li id='cell-108' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-108" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>CSF-1R MAb<br>
cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-108">
<div class="molecule-title">

<div class="mtitle DINBold">CSF-1R Monoclonal Antibody</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
"CSF-1R Monoclonal Antibody" is a new biologic entity being studied for the treatment of cancer.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-108").bind('click', function() {
    $("#content-108").bPopup();
    return false;
});
</script>
</li>
<li id='cell-109' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-109" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>FGFR3-ADC<br>cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-109">
<div class="molecule-title">

<div class="mtitle DINBold">FGFR3-ADC cancer</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
"FGFR3-ADC" is a new biologic entity being studied for the treatment of cancer.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-109").bind('click', function() {
    $("#content-109").bPopup();
    return false;
});
</script>
</li>
<li id='cell-110' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-110" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Met/EGFR Bispecific&nbspAntibody
<br>cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-110">
<div class="molecule-title">

<div class="mtitle DINBold">Met/EGFR Bispecific Antibody</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
"Met/EGFR Bispecific Antibody" is a new biologic entity being studied for the treatment of cancer.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-110").bind('click', function() {
    $("#content-110").bPopup();
    return false;
});
</script>
</li>
<li id='cell-111' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-111" class=" nme_cell tooltip_under" title="CLICK FOR MORE">
<div class="molecule-inner-content">
<label>Pan-Raf<br>inhibitor
<br>cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-111">
<div class="molecule-title">

<div class="mtitle DINBold">Pan-Raf inhibitor</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Oncology</label>
</div>
</div>

<div class="molecule-description">
"Pan-Raf inhibitor" is a new chemical entity being studied for the treatment of cancer.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-111").bind('click', function() {
    $("#content-111").bPopup();
    return false;
});
</script>
</li>
<li id='cell-112' class=' '>
<table cellspacing="0" cellpadding="0">
<tr>
<td>
<a id="click-content-112" class=" nme_cell tooltip_under" title="CLICK FOR MORE"><img class="minfoimg" align="absmiddle" src="./img/achived_milestone_molecule.png" alt=""/>
<div class="molecule-inner-content">
<label>PD-L1 MAb
<br>
cancer</label>
<label class="toolt">New Molecular Entity</label>
<label class="click_for_more">Click for more</label>
</div>
</a>
</td>
</tr>
</table>

<div class="content-popup " id="content-112">
<div class="molecule-title">

<div class="minfobg"><img src="./img/achived_milestone_molecule.png" alt=""/></div>

<div class="mtitle DINBold">PD-L1 Antibody</div>
<div class="molecule-position">
<label>Phase I</label>
<label>Business area: Oncology</label>
<label style='display:block;'>Molecule That Achieved Milestone
</label>
</div>
</div>

<div class="molecule-description">
"PD-L1 Antibody" is a new biologic entity being studied for the treatment of cancer.
<br/><br/>
</div>
<a class="bClose">&nbsp;</a>
</div>
<script type="text/javascript">
$("#click-content-112").bind('click', function() {
    $("#content-112").bPopup();
    return false;
});
</script>
</li>
<li id='cell-113' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-114' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-115' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-116' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-117' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-118' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-119' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-120' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-121' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-122' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-123' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-124' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-125' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
<li id='cell-126' class=' empty'>
<span class=" empty_cell no_bg">&nbsp;</span>
</li>
</ul>
</div>

</div>

<div class="disclaimer">
<b>Pipeline Disclaimer</b><br/>The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new
indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules
to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 19, 2016. Lilly
assumes no duty to update this information.
<br><br>
For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.</div>
<p class="footer">
Property of Eli Lilly and Company.
</p>
</div>
<div id="content-right">

<div class="molecule-info2">
<h1>Legend</h1>
<a href="full_legend.html">
<div class="molecule-data"><img class="fl" align="absmiddle" src="./img/new_molecule.png" alt=""/>
<div class="molecule-text">New Molecule</div>
</div>
</a>
<a href="full_legend.html">
<div class="molecule-data"><img class="fl" align="absmiddle" src="./img/achived_milestone_molecule.png" alt=""/>
<div class="molecule-text">Molecule That Achieved Milestone
</div>
</div>
</a>
<a href="full_legend.html">
<div class="molecule-data"><img class="fl" align="absmiddle" src="./img/scientific_name_given.png" alt=""/>
<div class="molecule-text">Nonproprietary Name Granted</div>
</div>
</a>
<a href="full_legend.html">
<div class="molecule-data"><img class="fl" align="absmiddle" src="./img/later_phase_molecule.png" alt=""/>
<div class="molecule-text">Molecule Moved to Earlier Phase</div>
</div>
</a>
<a href="full_legend.html">
<div class="molecule-data"><img class="fl" align="absmiddle" src="./img/lost_molecule.png" alt=""/>
<div class="molecule-text">Lost Through Attrition</div>
</div>
</a>
<a href="full_legend.html">
<div class="molecule-data"><img class="fl" align="absmiddle" src="./img/checked.png" alt=""/>
<div class="molecule-text">Regulatory Approval Achieved</div>
</div>
</a>
<div class="molecule-data">
*Commercial Collaboration
</div>
</div>
<ul class="molecule-info">
<li>
<span class="nme_cell">
<b>NME</b>
</span>
</li>

<li>
<span class="nilex_cell">
<b>Select NILEX</b>
</span>
</li>

<li>
<span class="diagnostic_cell">
<b>Diagnostic</b>
</span>
</li>
</ul>
<div id="full_legend_link">
For more information about Lilly's interactive pipeline website,
<a href="full_legend.html">click here</a>
</div>
</div>
</div>
<div id="footer"></div>
</div>

<script type="text/javascript">
$(window).load(function() {
    var cCenterHeight = $('#content-center').height();
    var cLeftHeight = $('#content-left').height();
    var paddingTop = cCenterHeight - cLeftHeight - 10;
    if (paddingTop > 0) {
        //$('.footer').css('padding-top', parseInt(paddingTop)+'px');
    }
    $('.molecule-container').each(function() {

        if (!$(this).has('li').length) {
            $(this).css('padding', '0');
        }

        $(this).find('a.big').each(function() {

            var a_height = $(this).height();

            var label_height = $(this).find('label').height();
            if (label_height != 0) {
                $(this).find('label').css('padding-top', parseInt(((a_height - label_height) / 2) - 5));
            } else {
                $(this).find('label').css('padding-top', 12);
            }
        });

    });
    //Set default open/close settings $('.molecule-container').hide(); //Hide/close all containers $('.cells-container-inner h1:last').addClass('active').next().hide();

});
</script>

<script type="text/javascript">
$(document).ready(function() {
    // align text in center
    $('.molecule-info2 .molecule-data').each(function() {
        var molecule_text_height = $(this).children('.molecule-text').height();
        if (molecule_text_height < 23) {
            $(this).children('.molecule-text').css('padding-top', (23 - molecule_text_height) / 2);
        }
    });
    //On Click
    $('.cells-container-inner h1.toggle').click(function() {
        if ($(this).hasClass('active')) {
            $(this).toggleClass('active').next().slideUp(); //Add "active" state to clicked trigger and slide down the immediate next container
            $(this).children('label').toggleClass('exp_open');
        } else {
            $(this).toggleClass('active').next().slideDown(); //Add "active" state to clicked trigger and slide down the immediate next container
            $(this).children('label').toggleClass('exp_open');
        }
        return false; //Prevent the browser jump to the link anchor
    });
    $('.molecule-container').each(function() {
        var i = 0;
        var j = 0;
        var a = new Array(6);
        $(this).find('li').each(function() {
            if ($(this).hasClass('empty')) {
                a[i] = $(this);
                j++;
            }
            i++;
            if (j == 6) {
                for (var k = 0; k < 6; k++) {
                    a[k].remove();
                }
            }
            if (i == 6) {
                i = 0;
                j = 0;
            }
        });
    });
});
</script>
<!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2010 WebTrends Inc.  All rights reserved. -->
<!-- Version: 9.3.0 -->
<!-- Tag Builder Version: 3.1  -->
<!-- Created: 2/10/2011 5:17:20 PM -->
<script src="webtrends.js" type="text/javascript"></script>
<!-- ----------------------------------------------------------------------------------- -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- ----------------------------------------------------------------------------------- -->
<script type="text/javascript">
        //<![CDATA[
var _tag = new WebTrends();
_tag.dcsGetId();

        //]]>
</script>
<script type="text/javascript">
        //<![CDATA[
_tag.dcsCustom = function() {
    // Add custom parameters here. _tag.DCSext.param_name=param_value;
}
_tag.dcsCollect();

        //]]>
</script>
<noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="http://statse.webtrendslive.com/dcskykqjqvz5bd05pjea7z15r_7k3s/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.3.0&amp;WT.dcssip=www.lilly.com,lilly.com,elilly.com"/></div>
</noscript>
<!-- END OF SmartSource Data Collector TAG -->
</body>
</html>
